Latest news with #Suryaprakash
Yahoo
31-03-2025
- Health
- Yahoo
Cell therapy for male urethral stricture: BEES-HAUS clinical application in Edogawa Hospital Japan, reports Dr. Akio Horiguchi in IMORU.
Technology transfer from India to Japan, accomplished by GN Corporation TOKYO, March 31, 2025--(BUSINESS WIRE)--Urethral stricture affecting men of all ages, with increasing incidence after 55, is a recurring problem despite several treatment options. By transplanting autologous lab-engineered buccal tissue cells (BEES-HAUS), Dr Akio Horiguchi successfully accomplished the first clinical transplantation in Edogawa Hospital, Japan as per Japanese Regenerative Medicine law, and presented in International Meeting Of Reconstructive Urology (IMORU) in Hamburg, Germany. Safety and efficacy clinically, reported earlier by Dr Suryaprakash from India, triggered this tech-transfer feat, spearheaded by GN Corporation. Urethral lumen is a delicate tissue, when damaged, inflammation and fibrosis lead to stricture. While idiopathic causes comprise the majority, radiation therapy for prostate cancer, trauma and infection are other causes. At early stages, endoscopic dilatation or urethrotomy are undertaken, but disease recurrence is common, causing difficulty in voiding urine, sexual dysfunction and infertility. Repeated interventions make the diseased segment longer and at some point, require a buccal tissue urethroplasty, where a large tissue from the mouth is harvested and used as a graft, causing oral morbidity. In BEES-HAUS procedure, cells from a small buccal tissue, cultured in the lab are transplanted, that cover and replace the damaged urethral epithelium, proven clinically and pre-clinically, healing the urethra and preventing recurrence. BEES-HAUS technology uses a hybrid combination of 2D cultured fibroblast like cells secreting IGF-1, yielding paracrine healing effect and 3D thermo-reversible gelation polymer cultured cells that engraft and restore the epithelial integrity, considered as the first of its kind feat in regenerative medicine. BEES-HAUS therapy could be recommended at earlier stages of the disease as well, after validations, opined Dr. Horiguchi. The Indo-Japan team has standardized the tissue engineering procedure, engraftment of cells on epithelial surface, transport of buccal tissue from hospital to lab and harvested cells back to hospital using a nano-polymer cell and tissue transportation cocktail, making the entire procedure highly efficient, end to end. Based on inter-disciplinary research by GN Corporation since 2008 with NCRM, Chennai, Tamilnadu, India, after having yielded a clinical solution and successful tech-transfer to Edogawa Hospital, Japan, GN Corporation has now signed a MoU with Soulsynergy, Mauritius. This partnership will propagate cell-based therapies for urethral stricture, corneal regeneration and AIET for cancer, making Mauritius, a healthcare technology cum medical tourism hub for African continent and Indian ocean rim countries. View source version on Contacts Samuel JK Abrahaminfo@ Sign in to access your portfolio
Khaleej Times
27-02-2025
- Health
- Khaleej Times
Experts urge India to rewrite clinical trial rules to boost global market share
India should take a page from the playbook of countries such as China and Australia if it wants a larger share of the global clinical trials market, healthcare experts said at an industry conference. As of 2022, India held an 8 per cent share in global clinical trials — which evaluate the safety and effectiveness of new treatments — compared to China's 29 per cent, the US's 25 per cent, and 38 per cent for the rest of the world, data from consultancy PwC showed. "There's a lot to learn from what other countries have done to make them clinical trial destinations," BCG India partner Smruthi Suryaprakash said, pointing out that China saw an increase in innovation after easing regulations, while Australia has benefited from offering significant tax incentives. India's clinical trials research market is rapidly expanding, supported by a diverse patient base, cost-effective solutions, and a growing hospital network, according to US-based GrandView Research, which forecasts revenues exceeding $2 billion by 2030. "India will be able to capture the clinical trial (market) if we can really work on the speed. I think speed is what is really important to sponsors, either with regulator or being able to recruit patients faster," Suryaprakash added. Suryaprakash, along with other experts, was speaking as part of a panel at the BioAsia conference in the southern Indian state of Telangana. Rajeev Raghuvanshi, who heads India's drug regulator, said it was working to make the regulatory process more streamlined for global trials in India, based on feedback from stakeholders. "We have aligned things every year on average for the last three years," the drugs controller general of India said. The agency which revamped its trial rules in 2019, had approved about 160 trials in the last three years, he added. Recruiting the right patients Allowing sponsors to raise awareness among patients, such as through advertisements of ongoing studies, would also help India advance as a recruitment site, the experts said. Advertising studies for experimental treatments could be helpful, especially for patients with rare diseases without many treatment options. It is a common practice in countries such as the US and the UK. "You're not able to recruit into the trial because they (patients) do not know that it exists," said Padmaja Lokireddy, an oncologist at Apollo Hospitals. That needs to change, experts said. Some other experts highlighted challenges related to preparing a clinical trial site, ensuring it meets global safety standards and recruiting the right patients.
Zawya
27-02-2025
- Health
- Zawya
Healthcare experts urge India to rewrite clinical trial rules to boost global market share
India should take a page from the playbook of countries such as China and Australia if it wants a larger share of the global clinical trials market, healthcare experts said at an industry conference. As of 2022, India held an 8% share in global clinical trials - which evaluate the safety and effectiveness of new treatments - compared to China's 29%, the U.S.'s 25%, and 38% for the rest of the world, data from consultancy PwC showed. "There's a lot to learn from what other countries have done to make them clinical trial destinations," BCG India partner Smruthi Suryaprakash said, pointing out that China saw an increase in innovation after easing regulations, while Australia has benefited from offering significant tax incentives. India's clinical trials research market is rapidly expanding, supported by a diverse patient base, cost-effective solutions, and a growing hospital network, according to U.S.-based GrandView Research, which forecasts revenues exceeding $2 billion by 2030. "India will be able to capture the clinical trial (market) if we can really work on the speed. I think speed is what is really important to sponsors, either with regulator or being able to recruit patients faster," Suryaprakash added. Suryaprakash, along with other experts, was speaking as part of a panel at the BioAsia conference in the southern Indian state of Telangana. Rajeev Raghuvanshi, who heads India's drug regulator, said it was working to make the regulatory process more streamlined for global trials in India, based on feedback from stakeholders. "We have aligned things every year on average for the last three years," the drugs controller general of India said. The agency which revamped its trial rules in 2019, had approved about 160 trials in the last three years, he added. RECRUITING THE RIGHT PATIENTS Allowing sponsors to raise awareness among patients, such as through advertisements of ongoing studies, would also help India advance as a recruitment site, the experts said. Advertising studies for experimental treatments could be helpful, especially for patients with rare diseases without many treatment options. It is a common practice in countries such as the U.S. and the U.K. "You're not able to recruit into the trial because they (patients) do not know that it exists," said Padmaja Lokireddy, an oncologist at Apollo Hospitals. That needs to change, experts said. Some other experts highlighted challenges related to preparing a clinical trial site, ensuring it meets global safety standards and recruiting the right patients. (Reporting by Bhanvi Satija, Kashish Tandon and Rishika Sadam in Hyderabad; Editing by Manas Mishra, Dhanya Skariachan and Tasim Zahid)
Reuters
27-02-2025
- Health
- Reuters
Healthcare experts urge India to rewrite clinical trial rules to boost global market share
HYDERABAD Feb 27 (Reuters) - India should take a page from the playbook of countries such as China and Australia if it wants a larger share of the global clinical trials market, healthcare experts said at an industry conference. As of 2022, India held an 8% share in global clinical trials - which evaluate the safety and effectiveness of new treatments - compared to China's 29%, the U.S.'s 25%, and 38% for the rest of the world, data from consultancy PwC showed. "There's a lot to learn from what other countries have done to make them clinical trial destinations," BCG India partner Smruthi Suryaprakash said, pointing out that China saw an increase in innovation after easing regulations, while Australia has benefited from offering significant tax incentives. India's clinical trials research market is rapidly expanding, supported by a diverse patient base, cost-effective solutions, and a growing hospital network, according to U.S.-based GrandView Research, which forecasts revenues exceeding $2 billion by 2030. "India will be able to capture the clinical trial (market) if we can really work on the speed. I think speed is what is really important to sponsors, either with regulator or being able to recruit patients faster," Suryaprakash added. Suryaprakash, along with other experts, was speaking as part of a panel at the BioAsia conference in the southern Indian state of Telangana. Rajeev Raghuvanshi, who heads India's drug regulator, said it was working to make the regulatory process more streamlined for global trials in India, based on feedback from stakeholders. "We have aligned things every year on average for the last three years," the drugs controller general of India said. The agency which revamped its trial rules in 2019, had approved about 160 trials in the last three years, he added. RECRUITING THE RIGHT PATIENTS Allowing sponsors to raise awareness among patients, such as through advertisements of ongoing studies, would also help India advance as a recruitment site, the experts said. Advertising studies for experimental treatments could be helpful, especially for patients with rare diseases without many treatment options. It is a common practice in countries such as the U.S. and the U.K. "You're not able to recruit into the trial because they (patients) do not know that it exists," said Padmaja Lokireddy, an oncologist at Apollo Hospitals ( opens new tab. That needs to change, experts said. Some other experts highlighted challenges related to preparing a clinical trial site, ensuring it meets global safety standards and recruiting the right patients.
